Cargando…
Transdermal hormone therapy and bone health
The clinical aftermath of the reporting of the initial findings of the Women’s Health Initiative (WHI) in 2002 was a profound reduction in the use of hormone therapies by menopausal women. This reduction led to a well documented increase in vasomotor symptoms and vaginal atrophy among those women wh...
Autor principal: | Shulman, Lee P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2544369/ https://www.ncbi.nlm.nih.gov/pubmed/18488878 |
Ejemplares similares
-
Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review
por: Goldštajn, Marina Šprem, et al.
Publicado: (2022) -
Transdermal hormone therapy in postmenopausal women: A review of metabolic effects and drug delivery technologies
por: Kopper, Nathan W, et al.
Publicado: (2009) -
Transdermal delivery for gene therapy
por: Singh, Parbeen, et al.
Publicado: (2022) -
The effect of transdermal gender-affirming hormone therapy on markers of inflammation and hemostasis
por: Schutte, Moya H., et al.
Publicado: (2022) -
Transdermal delivery of combined hormonal contraception: a review of the current literature
por: Galzote, Rosanna M, et al.
Publicado: (2017)